#1 Clinical Trials Search in Europe

Nms-03305293

NMS-03305293 is a novel drug currently being studied in clinical trials for patients with advanced or metastatic solid tumors and recurrent glioblastoma. This PARP inhibitor is being evaluated for its safety, effectiveness, and potential to improve outcomes in patients who have limited treatment options. The trials are exploring NMS-03305293 both as a single agent and in combination with other therapies, offering hope for patients with various types of cancer.

Table of Contents

What is NMS-03305293?

NMS-03305293 is a new drug currently being studied in clinical trials. It belongs to a class of medications called PARP inhibitors[1]. PARP inhibitors are a type of targeted therapy that work by blocking a specific enzyme in cancer cells, making it harder for these cells to repair their DNA and survive.

How does it work?

As a PARP inhibitor, NMS-03305293 targets an enzyme called poly (ADP-ribose) polymerase (PARP). This enzyme helps repair damaged DNA in cells. By blocking PARP, the drug makes it difficult for cancer cells to fix their DNA, which can lead to cell death. This approach is particularly effective in cancers with certain genetic mutations, such as BRCA mutations, which already have difficulty repairing DNA[1].

What conditions does it treat?

NMS-03305293 is being studied for the treatment of several types of advanced or metastatic solid tumors. These include:

  • HER2-negative breast cancer: A type of breast cancer that doesn’t have high levels of a protein called HER2
  • Epithelial ovarian cancer: The most common type of ovarian cancer, which starts in the cells covering the ovary
  • Castration-resistant prostate cancer (CRPC): A type of prostate cancer that continues to grow even when testosterone levels are low
  • Pancreatic cancer
  • Glioblastoma: An aggressive type of brain cancer
  • Diffuse glioma: Another type of brain tumor[1][2]

The drug is being studied particularly in patients with gBRCA mutations. These are genetic changes that can increase the risk of certain cancers and may make them more responsive to PARP inhibitors[1].

Current Clinical Trials

NMS-03305293 is currently being tested in two main clinical trials:

  1. A Phase I study for patients with advanced or metastatic solid tumors. This trial aims to determine the safety, tolerability, and preliminary effectiveness of NMS-03305293 in patients who have exhausted standard treatment options[1].

  2. A Phase I/II study combining NMS-03305293 with another drug called temozolomide (TMZ) for patients with recurrent glioblastoma and diffuse gliomas. This study is looking at both the safety and effectiveness of this drug combination[2].

Administration and Dosing

NMS-03305293 is taken orally (by mouth). The exact dosing schedule varies depending on the specific trial and treatment phase. In general, it’s taken daily for either 21 or 28 days in repeated 4-week cycles[1][2]. The optimal dose and schedule are still being determined through these clinical trials.

Potential Side Effects

As NMS-03305293 is still in clinical trials, its full side effect profile is not yet known. The trials are carefully monitoring for any adverse events (side effects). These could include changes in blood tests, heart function tests, or other physical symptoms. The severity of side effects will be graded according to standardized criteria used in cancer research[1][2].

Future Prospects

The ongoing clinical trials will help determine how effective NMS-03305293 is in treating various types of cancer, either alone or in combination with other drugs. If the results are promising, it could potentially become a new treatment option for patients with certain types of advanced cancers, particularly those with specific genetic mutations[1][2].

Aspect Details
Drug Name NMS-03305293
Drug Type PARP inhibitor
Administration Oral
Cancer Types Studied Advanced/metastatic solid tumors, including HER2-negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer, pancreatic cancer, and glioblastoma
Study Phases Phase I and Phase I/II
Primary Objectives Safety, tolerability, preliminary antitumor activity, and determination of recommended Phase 2 dose
Secondary Objectives Pharmacokinetics, objective tumor response, progression-free survival, overall survival
Combination Therapy Studied in combination with temozolomide for recurrent glioblastoma
Patient Population Adults with advanced/metastatic solid tumors who have exhausted standard treatment options or for whom standard therapy is unsuitable

FAQ

  • What is NMS-03305293? NMS-03305293 is a PARP inhibitor drug being studied in clinical trials for patients with advanced or metastatic solid tumors and recurrent glioblastoma. It is designed to target cancer cells and potentially improve outcomes for patients who have limited treatment options.
  • What types of cancer are being studied with NMS-03305293? The clinical trials are focusing on several types of cancer, including HER2-negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC), pancreatic cancer, and glioblastoma (a type of brain cancer).
  • How is NMS-03305293 administered? NMS-03305293 is administered orally. In the trials, patients receive the drug on various schedules, such as Days 1-21 or Days 1-28 in repeated 4-week cycles, depending on the specific study design.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety and tolerability of NMS-03305293, determine the appropriate dosage, evaluate its effectiveness in treating various cancers, and study how the drug behaves in the body (pharmacokinetics).
  • Are there any combination therapies being tested with NMS-03305293? Yes, one of the trials is studying the combination of NMS-03305293 with temozolomide (TMZ) in patients with recurrent glioblastoma. This combination approach aims to explore potential synergistic effects in treating brain cancer.

Ongoing Clinical Trials on Nms-03305293

  • Study of NMS-03305293 and Temozolomide for Adults with Recurrent Glioblastoma

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands

Glossary

  • PARP inhibitor: A type of drug that blocks an enzyme called poly (ADP-ribose) polymerase. PARP inhibitors are used to treat certain types of cancer, particularly those with specific genetic mutations.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord.
  • HER2-negative breast cancer: A type of breast cancer that does not have high levels of a protein called human epidermal growth factor receptor 2 (HER2).
  • Castration-resistant prostate cancer (CRPC): Prostate cancer that continues to grow even when the amount of testosterone in the body is reduced to very low levels.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and eliminated.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.

References